Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

When is the best time for ovarian cancer surgery?

NCT ID NCT02828618

Disease control Sponsor: AGO Study Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the best time to perform surgery for advanced ovarian cancer. It compares having surgery right away versus after a few rounds of chemotherapy. The goal is to see which approach helps people live longer. About 800 women with stage IIIB-IV ovarian cancer are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

797 people

The number who actually took part.

Start date

Jul 2016

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer FIGO stage IIIB-IV (IV only if resectable metastasis) * Females aged ≥ 18 years * Patients who have given their written informed consent * Good performance status (ECOG 0/1) * Good ASA score (1/2) * Preoperative CA 125/CEA ratio ≥ 25 (if CA-125 is elevated)\* * If \<25 and/or biopsy with non-serous, non-endometroid histology, esophago-gastro-duodenoscopy (EGD) and colonoscopy mandatory to exclude gastrointestinal primary cancer * Assessment of an experienced surgeon, that based on all available information, the patient can undergo the procedure and the tumor can potentially be completely resected * Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. * Platelet count ≥ 100 x 109/L. * Renal function: Serum-Creatinine ≤ 1.5 x institutional upper limit normal (ULN). * Hepatic function: * Bilirubin ≤ 1.5 x ULN. * SGOT ≤ 3 x ULN * Alkaline phosphatase ≤ 2.5 x ULN. * Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1. Exclusion Criteria: * Non epithelial ovarian malignancies and borderline tumors * Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity. * Recurrent ovarian cancer * Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy * Unresectable parenchymal lung metastasis, liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis * Clinical relevant dysfunctions of blood clotting (including drug induced) * Any significant medical reasons, age or performance status that will not allow to perform the study procedures (estimation of investigator) * Pregnancy * Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent * Any reasons interfering with regular follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie

    Berlin, 13353, Germany

  • European Institute of Oncology; Gynecologic Cancer Surgery

    Milan, Italy

  • Fondazione IRCCS Istituto Nazionale Tumori - Milan

    Milan, Italy

  • Hôpital Européen Georges Pompidou (HEGP)

    Paris, France

  • Imperial College London, Hammersmith Hospital, Surgery&Cancer

    London, W12 OHS, United Kingdom

  • Institut Bergonié

    Bordeaux, France

  • Institute Gustave Roussy

    Villejuif, 94805, France

  • Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli

    Naples, Italy

  • Kaiserswerther Diakonie; Florence-Nightingale-Hospital

    Düsseldorf, Germany

  • Karolinska University Hospital

    Solna, 17176, Sweden

  • Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München

    München, 81377, Germany

  • Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gyn. Onkologie

    Essen, 45136, Germany

  • Klinikum rechts der Isar, Frauen- und Poliklinik

    München, 81675, Germany

  • Medical University of Vienna

    Vienna, A-1090, Austria

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Skane University Hospital

    Lund, 22185, Sweden

  • University Hospital, Rigshospitalet

    Copenhagen, 2100, Denmark

  • Universitätsklinikum Carl Gustav Carus Dresden, Klinik & Poliklinik f. Frauenheilkunde & Geburtshilfe

    Dresden, 01307, Germany

  • Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie

    Hamburg, 20246, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.